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Review
Coronaviruses, a large group of single-stranded ribonu-
cleic acid (RNA) viruses, cause illnesses in humans 
ranging from the common cold to severe disease includ-
ing severe acute respiratory syndrome (SARS) and 
Middle East respiratory syndrome (MERS).In December 
2019 in Wuhan, China, a new coronavirus appeared that 
virologists believe originated in bats and transferred to 
humans via an intermediary animal host (Andersen et al., 
2020). The new virus is now known as the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) and 
causes the disease recognized by the World Health 
Organization (WHO) as 2019 new coronavirus disease 
or COVID-19 (MayoClinic, 2020). As a novel virus with 
little or no preexisting immunity to it, the SARS-CoV-2 
spread through China and many countries. Recognizing 
its worldwide spread, in March 2020 the WHO declared 
COVID-19 as the first pandemic caused by a new coro-
navirus (WHO, 2020c).
COVID-19 infection can be asymptomatic or cause 
symptoms such as cough, fever, and shortness of breath 
that usually appear within 5 to 6 days of infection. While 
the disease appears to produce mild to moderate illness 
in most people, in others the infection can cause life-
threatening pneumonia and death. While each day scien-
tists learn more about the disease, the current consensus 
is that transmission occurs primarily from droplets trans-
mitted by person-to-person contact as well as when a 
person touches a virally contaminated surface or object 
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Abstract
Coronaviruses are single-stranded ribonucleic acid viruses that can cause illnesses in humans ranging from the common 
cold to severe respiratory disease and even death.In March 2020, the World Health Organization declared the 2019 
novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
as the first pandemic. Compared to women, most countries with available data report that men with COVID-19 have 
greater disease severity and higher mortality. Lab and animal data indicate that men respond differently to the SARS-
CoV-2 infection, offering possible explanations for the epidemiologic observations. The plausible theories underlying 
these observations include sex-related differences in angiotensin-converting enzyme 2 receptors, immune function, 
hormones, habits, and coinfection rates.In this review we examine these factors and explore the rationale as to 
how each may impact COVID-19. Understanding why men are more likely to experience severe disease can help in 
developing effective treatments, public health policies, and targeted strategies such as early recognition and aggressive 
testing in subgroups.
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and then touches his or her mouth, nose, or eyes (Li, 
Guan, et al., 2020).
Pathophysiology
Named after its surface spikes that give it a crown-like 
appearance, the coronavirus usually first infects the cells 
lining the upper respiratory tract. The surfaces of these 
cells are rich in angiotensin-converting enzyme 2 (ACE2) 
receptors and the corona spikes act like a “key,” binding 
to the ACE2 receptor or “lock” to open an entry for the 
virus into the cell.Once inside the cell, the virus diverts 
the cell’s machinery from its normal function and turns 
the cell into viral factories that produce and release large 
numbers of new viruses that then target more cells.Early 
symptoms are mild, resembling the common cold, and in 
about 80% of individuals the immune system resolves the 
infection without further progression.In about 15% of 
individuals the virus infects the cells of the lower respira-
tory tract, leading to cough, fever, shortness of breath, 
and pneumonia (Wu & McGoogan, 2020). Lower respira-
tory infection triggers a heightened immune response 
sending signals to release cytokines, which can cause a 
high temperature and general malaise. If the immune 
function is effective, the virus can be effectively sup-
pressed and the affected person enters the recovery phase.
Roughly 5% of individuals experience life-threatening 
respiratory failure and multiorgan dysfunction. If the 
virus disrupts the immune response and triggers excess 
inflammation, the lung alveoli begin to fill with fluid and 
severely compromise gas exchange. The virus enters the 
circulation from the lung and can affect other organs, 
which have a large number of ACE2 receptors on their 
cell surfaces. The risk of disease progression and devel-
oping life-threatening disease is higher if the patient is 
older, is immunocompromised, or has comorbidities such 
as hypertension and diabetes (Lin et al., 2020). The exact 
case fatality rate remains uncertain but is likely in the 1% 
to 2% range (Cascella et al., 2020; WHO, 2020b).
Epidemiology
Worldwide there have been over 12,000,000 COVID-19 
cases and more than 550,000 deaths. As of July 12, 2020, 
the United States reported more than 3,000,000 cases and 
135,000 deaths (WHO, 2020a).
Current reports continue to reflect earlier epidemio-
logical observations that while SARS-CoV-2 infects all 
age groups, older men with chronic illnesses appear to be 
more severely affected.The first suggestion that men 
might be disproportionately affected emerged from an 
early report from China (Chen et al., 2020). Since then 
similar trends have been observed in other countries. In 
Italy, a report on 3,200 COVID-19-related deaths showed 
higher death rates for men than for women across all age 
groups, with men accounting for about 70% of deaths 
(Onder et al., 2020). To date, most countries with avail-
able data also report a disproportional mortality burden 
among men, with the largest male-to-female ratios seen 
in the Dominican Republic, Netherlands, Denmark, and 
Philippines (GlobalHealth5050, 2020).
Not all states in the United States break down their 
COVID-19 reporting by sex. However, in a recent analy-
sis of the 26 states with >2,000 COVID-19 cases, half of 
the states disaggregated data using sex as a variable. 
Similar to global findings, these 13 states reported that 
men are twice as likely to die from COVID-19 than wom-
enare (Bischof et al., 2020). Disparities in outcomes 
between men and women in illnesses caused by patho-
genic coronaviruses are not new.In both the SARS 
outbreak in 2002–2003 and the MERSof 2012, men expe-
rienced higher mortality rates (Karlberg et al., 2004).
Data from the U.S. Centers for Disease Control and 
Prevention on COVID-19 hospitalization and mortality 
rates also demonstrate disparities among racial and ethnic 
minorities, with mortality rates for African American and 
Latino men exceeding those for White or Asian males. 
The research literature exploring racial disparities and 
COVID-19 is limited (Shah et al., 2020), but after adjust-
ing for differences in sociodemographic and clinical 
characteristics, race was no longer associated with 
increased mortality(Price-Haywood et al., 2020). These 
findings make it likely that the greater prevalence of con-
ditions such as obesity, diabetes, and hypertension and 
socioeconomic factors including poorer access to testing 
and treatment account for most if not all the mortality dif-
ference among men of color (Yancy, 2020).
The reason why mortality rates differ between men 
and women remains uncertain. Proposed explanations 
include differences in ACE2 receptors, immune function, 
hormones, habits, coinfection rates, and gender influ-
ences related to masculinity.In this review we examine 
these factors and explore the rationale as to how each 
may impact COVID-19.
Potential Factors Impacting 
COVID-19
ACE2 Receptors
ACE2 receptors are found on the cell surface and help 
regulate a protein called angiotensin II.Angiotensin II can 
increase blood pressure and inflammation, potentially 
damaging blood vessel linings and causing other tissue 
injury. ACE2 plays a role in converting angiotensin II to 
other molecules that counteract its effects.
Infection with SARS-CoV-2 begins when the virus 
binds to a host cell’s ACE2 receptor, creating a cellular 
doorway for the virus to infect the cell (Verdecchia et al., 
2020). ACE2 is commonly expressed on the epithelial 
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cells of the alveoli, trachea, and bronchi, and bronchial 
serous glands of the respiratory tract, making them tar-
gets for the SARS-CoV2 virus. Studies suggest that men 
have more ACE2 receptors than women do and express 
more ACE2 in their lungs and heart, potentially explain-
ing the male predilection for more severe disease 
(Cascella et al., 2020; Sama et al., 2020). Interestingly, 
there are differences in ACE2 receptors in the reproduc-
tive organs, with the testes having significantly more 
ACE2 receptors than the ovaries (Sharma et al., 2020). 
Also, when the virus binds to ACE2, it inhibits the recep-
tor’s normal function, which includes inhibiting inflam-
mation. An imbalance between proinflammatory and 
anti-inflammatory mechanisms can increase tissue injury, 
especially in the heart and lung. Differences in ACE2 
receptors may adversely affect inflammatory control, 
leading to a more persistent viral presence and damaging 
inflammation in men. Some evidence suggests that ACE2 
may also be higher in patients with hypertension, diabe-
tes, and coronary heart disease and may in part explain 
the association of these comorbidities with COVID-19 
severity and mortality (Sama et al., 2020).
Immune System Differences
Differences in immune defenses likely contribute to the 
discrepancies in COVID-19 outcomes between men and 
women. Females typically generate higher innate and 
adaptive immune responses when compared with males 
and mount a more vigorous response to most invading 
pathogens (Araneo et al., 1991; Barrat et al., 1997; Roberts 
et al., 2001). Previous studies point to better outcomes for 
respiratory infections in women,and men with pneumonia 
are more likely to come to the hospital sicker and more 
likely to die from pneumonia than women are, even when 
controlling for behaviors and chronic conditions (Reade 
et al., 2009). Epidemiological evidence from influenza 
outbreaks and pandemics also reveals a higher morbidity 
and mortality for menthan that for women in some age 
groups (Klein et al., 2012).In animal studies, male animals 
have poorer immune responses when exposed to the coro-
navirus and experience more damage to their lungs 
(Vermillion et al., 2018).For both SARS and the MERS 
coronavirus outbreaks, men fared worse than women did.
A key difference in women that may explain their 
greater natural immune response is that women have two 
X chromosomes in their cells, while men have one. The X 
chromosome contains several important genes related to 
immunity and immune regulation that are extensively 
involved in shaping sex-specific innate and adaptive 
immune responses (Schurz et al., 2019). Although X 
chromosome inactivation might be expected to balance 
female and male immune gene expression, several genes 
on the X chromosomes can escape inactivation, which 
results in women producing more proteins coded by these 
genes.While the mechanism of how these genes become 
active remains uncertain, X gene activation may account 
for most immune differences between the sexes.An 
example relevant to coronavirus infection is the X chro-
mosome gene coding for the protein called Toll-like 
receptor 7 (TLR7). TLR7 helps control the innate immune 
response by recognizing single-stranded RNA of viral 
origin, like an RNA coronavirus that might be overex-
pressed in women and contribute to clearing the SARS-
CoV2 faster (Souyris et al., 2018).
Sex Hormones
Sex hormones play a role in modulating the immune sys-
tem and contribute to variations seen in the immunologic 
responses of men and women. They help balance the 
immune response between combating a viral infection 
and triggering harmful inflammation. In general, the male 
sex hormone testosterone is immunosuppressive, while 
the female sex hormone estrogen tends to enhance the 
immune response (Klein et al., 2015).However, the 
impact of sex hormones on the SAR-CoV-2 is complex 
and not fully understood. A recent German study found 
that that critically ill male COVID-19 patients suffer from 
severe testosterone and dihydrotestosterone deficiencies 
and concluded that androgens are required to mount a 
strong antiviral immune response to combat infection 
in men (Schroeder et al., 2020). In contrast, another 
study found that prostate patients’ androgen deprivation 
therapy unexpectedly had better COVID-19 outcomes 
(Montopoli et al., 2020). They recognized that coronavi-
rus entry into human cells is primed by a cell surface ser-
ine protease, an enzyme encoded by the transmembrane 
serine protease 2 (TMPRSS2) gene (Paoloni-Giacobino 
et al., 1997). TMPRSS2 is an androgen-regulated gene 
found in the lung tissue, and Montopoli et al. (2020)  
speculated that testosterone stimulates TMPRSS2 gene 
expression, causing an increased susceptibility of men for 
severe SARS-CoV-2 infections.This theory suggests that 
androgen deprivation might block or decrease the sever-
ity of SARS-CoV-2 infections.
In contrast, some theoretical evidence suggests that 
low testosterone may be harmful.Inflammatory cytokines 
have a central role in the progression of COVID-19 infec-
tion. While a robust immune system is needed to fight an 
infection, unchecked, the response may be detrimental. 
Several studies demonstrate that hypogonadism is associ-
ated with increased proinflammatory cytokines and that 
testosterone may play a role in regulating the cascade of 
events leading to progression of COVID-19 infection due 
to the cytokine storm (Mohamad et al., 2019).
Since estrogen activates the immune system, an alterna-
tive explanation for the male/female difference for severe 
COVID-19 is that the female hormone estrogen may be 
protective. Evidence from both animal and human studies 
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supports this theory. Studies in female mice found that 
estrogen inhibited SARS-CoV replication, thereby protect-
ing the mice from infection (Robinson et al., 2014). Female 
mice with artificially induced estrogen suppression, oopho-
rectomy, or hysterectomy lose this protection when 
infected with the coronavirus and have mortality rates 
similar to those of male mice (Channappanavar et al., 
2017). The thought that estrogen might be protective sug-
gests that supplemental estrogen might boost the immune 
system. Ongoing trials are exploring whether giving men 
estrogen improves COVID-19 outcomes.
Reade et al. (2009) also studied immune function in the 
SARS-CoV-2 infection and found significant differences 
between men and women in their levels of tumor necrosis 
factor, interleukin-6, interleukin-10, antithrombin III, 
Factor IX, plasminogen activator inhibitor-1, and D-dimer. 
In some cases, concentrations for men were lower, while 
in others they were higher.Since sex hormones exert spe-
cific effects on male and female immunocompetence at 
both the cellular and the molecular level, it is not surpris-
ing to find differences in immune and inflammatory bio-
markers between men and women. For example, estrogen 
receptors are found in most cells of the innate and adap-
tive immune system including T cells, B cells, neutrophils, 
macrophages, dendritic cells, and natural killercells, while 
androgen receptors are prominent in T and B lymphocytes 
(Fish, 2008).Others also speculate that the different hor-
monal milieu could have a profound pathophysiological 
role in SARS-CoV-2 infection, with endogenous testo-
sterone leaving men more prone to develop more serious 
complications related to the SARS-CoV-2 infection 
(Salonia et al., 2020).Given the range of findings and tes-
tosterone’s multifaceted role in an intricate system, at this 
time perhaps all one can conclude is that testosterone can 
modulate the immune system. While in general testoster-
one causes a less robust immune response and estrogen 
helps females mount stronger immune responses, the 
more robust immune response in females may also lead to 
immunopathology resulting in fatal outcomes.Exactly 
how and if sex hormones positively or negatively affect 
outcomes in the milieu of COVID-19 remains uncertain 
and represents an area of future inquiry. Unraveling the 
exact role of the sex hormones offers the promise of devel-
oping beneficial therapeutic interventions.
Hygiene and Habits
Differences in hygiene and habits provide another explana-
tion for the sex-related differences seen with the SARS-
CoV-2 infection.Studies demonstrate that women wash 
their hands more often than men do, raising speculation 
that this might account for differences in COVID-19 
between men and women (Suen et al., 2019).In this case, 
there should be differences in the number of COVID- 
19 cases as well as mortality. However, available 
sex-disaggregated data for COVID-19 indicate that the 
number of COVID-19 cases appear to be comparable 
between men and women (Jin et al., 2020), making hygiene 
an unlikely explanation for a death rate that is two times 
greater for men than for women (Kocher et al., 2020).
An early theory was that higher smoking rates among 
men accounted for sex-related differences.Intuitively 
smokers would appear to be at greater risk from a respira-
tory infection especially since smokers are at greater risk 
for dying from influenza. While early studies from China 
suggested that smoking might account for the male–
female gap, later studies did not (Cai, 2020; Zhang et al., 
2020). A meta-analysis concluded that smoking was not a 
risk factorand surprisingly epidemiologic data from 
France suggested that smokers might even be at lower risk 
than nonsmokers (Fontanet et al., 2020; Vardavas & 
Nikitara, 2020).
Based on preliminary data from the United States, 
persons with underlying health conditions such as diabe-
tes mellitus, chronic lung disease, and cardiovascular 
disease appear to be at higher risk for severe COVID-19-
associated disease than persons without these conditions 
(CDC, 2020). Another possibility is that men tend to 
have higher rates of obesity, high blood pressure, diabe-
tes, cancer, and lung and cardiovascular disease, all of 
which have been linked to COVID-19 severity. While 
most studies continue to note a male predilection (Del 
Rio & Malani, 2020; Lawton, 2020), one New York–
based study found that when they factored these condi-
tions into the analysis, although being male increased 
the risk for hospitalization, sex was no longer one of the 
main risk factors for severe COVID-19 (Petrilli et al., 
2020).Currently sex-disaggregated data are incomplete 
(Shah et al., 2020), and this study highlights the need for 
both further study and including sex in COVID-19 data 
collection and reporting.
Finally, a study conducted in China found that men with 
COVID-19 in hospital were more likely than women to be 
carrying other viruses, including flu, and bacteria, suggest-
ing that carrying more microbial pathogens may contribute 
to the severity of COVID-19 symptoms (Li, Zhang, et al., 
2020).Typically, men have lower vaccine rates than women 
do for influenza and pneumonia, which might also account 
for a higher coinfection rate (Bergman, 2017).
Masculinity
Sex refers to the biological distinctions between males and 
female, while gender is the socially constructed differences 
between men and women that give rise to masculinity and 
femininity (Short et al., 2013). Masculinity is a social 
determinant of health (Lutfiyya et al., 2014) and aspects of 
masculinity intersect with biology in ways that may impact 
male COVID-19 mortality both currently and in the future. 
Toxic masculinity refers to cultural norms associated with 
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health-impeding behaviors and highlights engaging in 
risky behaviors such as the underutilization of health-care 
services, drinking to excess, and smoking. These and other 
unhealthy behaviors contribute to high blood pressure, car-
diovascular disease, and other comorbidities associated 
with increased SARS-CoV-2-related mortality.
Alcohol misuse is already a public health concern in 
the United States and over 9 million adult men have an 
alcohol use disorder (NIH, 2020). Alcohol has the physi-
ological potential to unfavorably complicate COVID-19 
in multiple ways, including adverse effects on the immune 
and respiratory systems, where excessive alcohol intake 
can damage the epithelial cells that line the lungs (Boe 
et al., 2009).Ultimately, by complicating COVID-19 pre-
vention, treatment, and recovery, excessive alcohol intake 
could certainly contribute to poorer outcomes in men.
While both male and females may delay seeking care, 
men tend to delay care more often and visit their doctors 
less often than women do (Mahalik et al., 2007). Arguably 
without the availability of effective early treatment, 
delaying care may not currently worsen COVID-19 but 
may become an important issue as new therapies merge.
For example, flu antivirals work best when administered 
early in the disease course (Papenburg et al., 2020). 
If drugs active against the SARS-CoV-2 virus act simi-
larly, then delaying care could adversely affect outcomes 
in the future.While not directly linked to COVID-19 
mortality, delaying care for other emergencies can indi-
rectly cause pandemic-related collateral damage (Gilligan 
& Gologorsky, 2020; Rosenbaum, 2020). During the 
COVID-19 pandemic, emergency room visits and 
hospitalization drastically decreased for heart disease 
and stroke, two potentially non-COVID-19-related life-
threatening conditions (Masroor, 2020). For example, 
large hospital systems in California, Massachusetts, and 
New York City have reported 43%–50% reductions in 
admissions for myocardial infarction (MI) and other 
acute cardiovascular conditions (Lange et al., 2020). 
Health behavior seems to be the likely cause, since a 
short-term decline in the incidence of heart disease of this 
magnitude is biologically implausible.Early interventions 
for these conditions can improve outcomes and mascu-
line behavior related to delaying or avoiding care might 
indirectly add to male mortality during the pandemic.
Wearing masks also seems to be a masculinity-related 
issue (Capraro & Barcelo, 2020). Data strongly suggest 
that wearing masks reduces viral transmission, yet 
fewer men than women wear masks (Chu et al., 2020). 
According to the survey of 2,459 people, men who 
shunned maskwearing cited concerns that face masks 
make them look weak and uncool (Capraro & Barcelo, 
2020). Opponents of maskwearing often view not wear-
ing masks in terms of bravery and risk-taking and, by 
implication, brand mask wearers as effete or cowardly. 
Resistance to mask wearing is not new and during the 
1918 flu pandemic, men needed more convincing to 
wear masks than women did.
Implications
There are several reasons why understanding how COVID-
19 affects men and women differently is important.One is 
that it can provide clues to understanding the pathophysiol-
ogy of the SARS-CoV-2 infection that might lead to suc-
cessful interventions. Already trials are in place to explore 
new options using existing drugs such as estrogen and/or 
progesterone therapy for men and angiotensin II receptor 
blockers (Healio, 2020; Sriram & Insel, 2020). The differ-
ence in TMPRSS2 gene expression suggests that drugs 
that inhibit the enzyme’s activity might be beneficial. 
Differences in immune responses between men and women 
are often overlooked in the design and implementation of 
vaccination strategies (Klein & Pekosz, 2014). With mul-
tiple candidate vaccines, it will be important to disaggre-
gate vaccine response by sex since vaccines may be more 
effective if matched to an individual’s biological sex.Also, 
as new vaccines are licensed, men and women may need a 
different dosage to trigger immunity.Undoubtedly it will 
be hard to ramp up production as new vaccines come on 
line; therefore, vaccine availability might be extended by 
giving lower doses to women without compromising effec-
tiveness.In addition to vaccines, other studies examining 
preventive and therapeutic treatment should include pro-
spective sex- and gender-sensitive analyses in light of how 
the SARS-CoV-2 differentially affects men and women. 
The Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) trial reported that in patients hospitalized 
with COVID-19, dexamethasone reduced mortality among 
those patients receiving respiratory support (Rezaie, 2020). 
At this stage the disease is dominated more by immunopa-
thology and less by active virus replication.The beneficial 
effect of dexamethasone likely depends on using the right 
dose, at the right time, and in the right patient. Sex-related 
immune response differences raise the possibility that dos-
ing and timing might need to be tailored to biologic sex 
(Horby et al., 2020).
Many men believe they are less vulnerable to COVID-19 
(Capraro & Barcelo, 2020), and that has consequences for 
how safe they really are during the pandemic. Educating 
men about their increased risk of dying from COVID-19 
might help in developing healthier behaviors.Having male 
role models demonstrating and endorsing healthy habits, 
wearing masks, and sharing their COVID-19 stories poten-
tially could help mitigate the spread of infection.Another 
noteworthy dimension of toxic masculinity is the tendency 
of some men to disregard the importance of personal hygiene 
and handwashing. Rebranding mask wearing and hand-
washing as altruistic, patriotic, and a service to vulnerable 
individuals might help men to view mask wearing, cleanli-
ness, and hygiene as being consistent with masculinity.
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Finally, a better understanding of COVID-19 risk fac-
tors can aide triage decisions, inform policy makers, and 
improve projections on how to distribute resources. The 
alarming rate at which minority men die from COVID-19 
highlights the need to address the conditions of their lives 
and the issues of insufficient resourcesand inequitable 
testing and treatment.
Conclusions
Compared to women, men infected with COVID-19 expe-
rience more disease severity and a higher mortality. Lab and 
animal data indicate that men respond differently to SAR-
CoV-2 infection and provide a basis for the epidemiologic 
findings.These results are driving new therapeutic options.
Continuing to collect data disaggregated by sex can help 
understand why men are more likely to experience severe 
disease (Baker et al., 2020). These insights can direct public 
health policies and targeted treatment strategies such as 
early recognition and aggressive testing that reduce mor-
bidity and mortality among men (Smith et al., 2020).
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